https://allsci.com/news/first-in-human-trials/pan-ras-inhibitor-clinical-trial-simcere-zaiming/ AllScien 2026-08-12T16:37:55.081342Z Simcere's pan-RAS inhibitor SIM0532 entering Phase I study https://allsci.com/news/safety-issues-crls/vykat-xr-safety-deaths-pws-organizations-call-for/ AllScien 2026-08-12T16:32:27.269391Z Patient groups call raise alarm over Vykat XR use after seven deaths reported https://allsci.com/news/venture-financing/remepy-series-a-funding-parkinsons-raises-usd-36m/ AllScien 2026-08-12T16:19:14.864534Z Merck KGaA partner Remepy raises USD 36m Series A for 'hybrid drug' platform https://allsci.com/news/venture-financing/androgenetic-alopecia-treatment-funding/ AllScien 2026-08-12T16:05:43.527514Z UC Irvine alopecia spinout Amplifica gets Lilly backing in USD 26m Series B https://allsci.com/news/approvals/ivonescimab-lung-cancer-approval-beats/ AllScien 2026-08-12T15:42:39.821603Z Ivonescimab expands China label as Summit awaits US test https://allsci.com/news/venture-financing/indupro-series-b-funding-adc-advances/ AllScien 2026-08-12T14:33:27.045522Z InduPro raises USD 77m as proximity-guided bispecific ADC enters clinic https://allsci.com/news/clinical-trials/dt120-odt-anxiety-treatment-definiums-beats/ AllScien 2026-08-12T14:11:40.904812Z Definium's LSD formulation scores second Phase III win in GAD https://allsci.com/news/first-in-human-trials/trop-2-adc-clinical-trial-bioray-launches/ AllScien 2026-08-12T13:34:42.900551Z BioRay moves dual-payload TROP2 ADC into the clinic https://allsci.com/news/clinical-trials/fda-clinical-trials-overseas-survey-finds/ AllScien 2026-08-12T13:26:00.133427Z Small US biotechs cite FDA barriers to first-in-human trials: survey https://allsci.com/news/research/daraxonrasib-resistance-pancreatic-cancer/ AllScien 2026-08-12T12:06:58.871750Z Daraxonrasib study reveals resistance mechanisms in pancreatic cancer https://allsci.com/news/funding/silence-therapeutics-divesiran-funding-raises-usd/ AllScien 2026-08-12T12:05:34.397599Z Silence upsizes USD 175m offering after divesiran Phase II win https://allsci.com/news/venture-financing/ai-drug-discovery-funding-beyang-raises-usd-30m/ AllScien 2026-08-12T12:01:28.384109Z Beyang bags USD 30m for AI-designed retinal, leukemia drugs https://allsci.com/news/news/wuxi-apptec-1260h-court-block-federal-temporarily/ AllScien 2026-08-12T11:50:40.377032Z WuXi AppTec wins court reprieve from Pentagon military designation https://allsci.com/news/regulatory/afuresertib-breast-cancer-china-approval/ AllScien 2026-08-12T10:00:57.731874Z Laekna takes aim at Truqap as China accepts afuresertib NDA https://allsci.com/news/regulatory/fda-ind-approval-glp-1-obesity-diabetes/ AllScien 2026-08-12T09:47:30.983431Z United Labs' oral GLP-1 drug cleared for US trials https://allsci.com/news/research/adc-biomarker-ai-nucleai-expands-work-with-gilead/ AllScien 2026-08-12T09:08:20.924697Z Gilead refreshes ADC biomarker collab with Nucleai https://allsci.com/news/funding/abcellera-funding-vasomotor-symptoms-raises-usd/ AllScien 2026-08-12T09:04:54.368553Z AbCellera offers up USD 200m in stock to support NK3 menopause antibody https://allsci.com/news/ipo-public-listing/vogenx-ipo-pricing-prices-usd-813m-at-high-end-of/ AllScien 2026-08-12T08:32:57.325756Z Vogenx prices USD 81.3m IPO to fund SGLT1-targeted mizagliflozin https://allsci.com/news/clinical-trials/cm512-phase-ii-chronic-rhinosinusitis-keymeds/ AllScien 2026-08-12T07:41:48.564565Z Keymed/Belenos’s twice-yearly TSLP × IL-13 bispecific clears Phase II https://allsci.com/news/licensing-and-partnerships/alvelestat-alpha-1-lung-disease-sentynl-gains-us/ AllScien 2026-08-11T17:08:20.659276Z Sentynl gains US rights to Mereo's Phase III alvelestat for alpha-1 lung disease https://allsci.com/news/licensing-and-partnerships/bofanglutide-licensing-agreement-europe/ AllScien 2026-08-11T16:52:59.370237Z Menarini bets EUR 726m on Gan & Lee’s biweekly GLP-1 https://allsci.com/news/funding/ab-science-funding-als-trial-raises-eur-142m-to/ AllScien 2026-08-11T16:10:19.728899Z AB Science raises EUR 14.2m to fund masitinib Phase III, AB8939 https://allsci.com/news/venture-financing/infinimmune-series-a-funding-raises-usd-75m-to/ AllScien 2026-08-11T14:24:30.715225Z Infinimmune raises USD 75m to bring IL-22 antibody into clinic https://allsci.com/news/venture-financing/epicrispr-series-c-funding-fshd-raises-usd-90m-to/ AllScien 2026-08-11T14:19:59.005073Z Epicrispr raises USD 90m to advance first-in-class epigenetic therapy into pivotal FSHD studies https://allsci.com/news/licensing-and-partnerships/oculis-privosegtor-acquisition-acquires-full/ AllScien 2026-08-11T14:14:22.102333Z Oculis rebuilds pipeline with Privosegtor buy from Accure https://allsci.com/news/funding/il-23-antagonist-funding-avere-raises-usd-500m-to/ AllScien 2026-08-11T13:52:56.568953Z Avere raises USD 500m for once-weekly IL-23R challenger to Icotyde https://allsci.com/news/funding/ipsc-neural-cell-therapy-funding-hopstem-secures/ AllScien 2026-08-11T13:42:42.931618Z China's Hopstem secures Series backing for iPSC neural cell therapy pipeline https://allsci.com/news/research/epigenetic-dna-repair-cancer-johns-hopkins/ AllScien 2026-08-11T13:29:30.543291Z Johns Hopkins probes macroH2A1 splicing as biomarker for PARP, TOP1 inhibitor response https://allsci.com/news/corporate-strategy/curium-abscint-acquisition-oncology-pet/ AllScien 2026-08-11T13:25:14.252226Z Curium continues to expand oncology PET pipeline with Abscint acquisition https://allsci.com/news/venture-financing/gene-therapy-funding-lifespan-vision-ventures/ AllScien 2026-08-11T13:16:21.018906Z Remedium Bio's obesity gene therapy platform picks up Lilly support in USD 10m Series A https://allsci.com/news/venture-financing/ai-drug-discovery-funding-aureka-closes-usd-100m/ AllScien 2026-08-11T13:07:54.905498Z Aureka closes USD 100m Series B to scale biological AI foundation models for drug discovery https://allsci.com/news/grants/ms-drug-screening-platform-artificial-axon-labs/ AllScien 2026-08-11T13:03:35.092823Z MIT spinout Artificial Axon gets NINDS backing for MS lesion-mimicking drug screening platform https://allsci.com/news/grants/velorum-nci-grant-lung-cancer-secures-126m-for/ AllScien 2026-08-11T12:58:51.910492Z Velorum secures NCI grant to advance heme-targeting lung cancer therapy to IND https://allsci.com/news/venture-financing/engasertib-phase-iii-trial-vaderis-raises-usd/ AllScien 2026-08-11T12:48:58.991600Z Vaderis raises USD 152m to advance engasertib into Phase III HHT trial https://allsci.com/news/research/nano-delivery-cancer-immunotherapy-university-of/ AllScien 2026-08-11T12:11:45.439348Z Michigan team develops oral metabolite drug to boost anti-PD-1 therapy https://allsci.com/news/research/cd19-car-t-cell-persistence-university-of/ AllScien 2026-08-11T10:58:17.772610Z UPenn researchers document decade-long CD19 CAR T cell persistence in Nature Medicine https://allsci.com/news/health/childhood-vaccine-recommendations-hhs/ AllScien 2026-08-11T08:54:12.425319Z Trump cuts US childhood vaccine schedule, targets MMR https://allsci.com/news/grants/universal-influenza-vaccine-scripps-research/ AllScien 2026-08-11T08:16:06.356238Z Scripps developing three-antigen nanoparticle platform for universal flu vaccine https://allsci.com/news/clinical-trials/sonelokimab-psoriatic-arthritis-hits-all/ AllScien 2026-08-11T07:59:40.633238Z MoonLake's sonelokimab meets all endpoints in Phase III psoriatic arthritis trial https://allsci.com/news/clinical-trials/divesiran-polycythemia-vera-silences-achieves-88/ AllScien 2026-08-11T07:46:49.459590Z Silence's divesiran achieves 88% response in Phase II PV trial with quarterly dosing https://allsci.com/news/clinical-trials/abcl635-hot-flashes-phase-ii-abcelleras-antibody/ AllScien 2026-08-11T07:13:49.979642Z AbCellera's NK3R antibody meets both endpoints in Phase II menopause study https://allsci.com/news/regulatory/fda-radiotherapy-drug-approval-blocks-itms-over/ AllScien 2026-08-10T18:15:51.265598Z FDA blocks ITM's radiotherapy drug over manufacturing defects, clinical data intact https://allsci.com/news/licensing-and-partnerships/ion-channel-drug-discovery-almirall-taps/ AllScien 2026-08-10T16:51:48.225522Z Almirall taps CrystalO's AI platform to discover ion channel drugs for skin disease https://allsci.com/news/licensing-and-partnerships/lacutamab-phase-iii-trial-sobi-funds-innates-with/ AllScien 2026-08-10T16:50:24.947417Z Sobi funds Innate's phase III lacutamab trial with USD 75 million upfront deal https://allsci.com/news/clinical-trials/sionna-cystic-fibrosis-drug-fails-sionnas-lead/ AllScien 2026-08-10T16:49:36.943623Z Sionna's lead cystic fibrosis program fails Phase IIa test, clouding NBD1 stabilizer strategy https://allsci.com/news/licensing-and-partnerships/novo-nordisk-aws-partnership-taps-as-preferred/ AllScien 2026-08-10T16:43:02.052703Z Novo Nordisk taps AWS as preferred cloud provider, launches London AI drug discovery hub